Patient
SITE015-0005
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2025-08-22
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 6
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-02 (study day 244); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-31 (study day 181); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-26 (study day 176); relationship: NOT RELATED
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-15 (study day 165); relationship: RELATED
Grade 1 Adrenal insufficiency — outcome: RECOVERED/RESOLVED; onset 2022-06-24 (study day 113); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-31 (study day 89); relationship: NOT RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.